| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg | |||
| 50mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
Bacterial riboflavin riboswitches
Ribocil-C targets the bacterial flavin mononucleotide (FMN) riboswitch, which controls the expression of de novo riboflavin (vitamin B2) biosynthesis in Escherichia coli and other bacteria. It acts as a synthetic analogue of FMN, binding to the riboswitch and inhibiting ribB gene expression. The compound also specifically targets dual FMN riboswitches that regulate RF biosynthesis and RF uptake in Staphylococcus aureus. |
|---|---|
| ln Vitro |
The flavin mononucleotide (FMN) riboswitch, which regulates the expression of de novo riboflavin (RF, vitamin B2) biosynthesis in Escherichia coli, is highly selectively inhibited by ribocil-C. In order to independently regulate the RF biosynthesis and uptake processes necessary for Staphylococcus aureus growth and pathogenesis, riboflavin-C specifically inhibits dual FMN riboswitches[1]. In order to inhibit ribB expression and RF synthesis, which in turn stops bacterial growth, Ribocil-C, a synthetic small-molecule FMN mimic, binds the FMN riboswitch of several GN bacteria, such as Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii[1][2].
Ribocil-C is a selective inhibitor of the FMN riboswitch that controls riboflavin biosynthesis. It can bind to FMN riboswitches in various Gram-negative bacteria, including E. coli, Pseudomonas aeruginosa, and Acinetobacter baumannii. By inhibiting ribB gene expression and RF synthesis, Ribocil-C exerts its antibacterial effects. The compound has been shown to inhibit bacterial cell growth. Specific IC50 values for growth inhibition against various strains are not detailed in the available summaries. |
| ln Vivo |
Increased dosage In comparison to sham-treated mice, the ribocil-C treatment groups (60 and 120 mg kg21 ribocil-C) show a dose-dependent reduction in bacterial burden of 1.87 and 3.29 log10[CFU per g spleen] reduction, respectively, without mortality or obvious toxicity effects[2].
Ribocil-C (60 mg/kg and 120 mg/kg) exhibited significant dose-dependent antibacterial efficacy in a mouse model. Compared to untreated control mice, the bacterial load (CFU/g) in the spleen was reduced by 1.87 and 3.29 log10, respectively. No significant mortality or toxicity was observed at the tested doses. This indicates that Ribocil-C has in vivo efficacy against bacterial infections and a favorable safety profile at effective doses. |
| Enzyme Assay |
The binding of Ribocil-C to the FMN riboswitch is assessed using an in vitro binding assay. The FMN riboswitch RNA is transcribed in vitro and incubated with varying concentrations of Ribocil-C. The binding affinity is measured using techniques such as isothermal titration calorimetry (ITC) or surface plasmon resonance (SPR) to determine the dissociation constant (Kd). Alternatively, a fluorescence-based assay can be used, where the riboswitch is labeled with a fluorophore, and the change in fluorescence upon ligand binding is monitored. Specific protocol details are not available.
|
| Cell Assay |
The antibacterial activity of Ribocil-C is assessed using standard broth microdilution assays to determine the minimum inhibitory concentration (MIC). Bacterial strains (e.g., E. coli, P. aeruginosa, A. baumannii) are grown in cation-adjusted Mueller-Hinton broth. Two-fold serial dilutions of Ribocil-C are prepared in 96-well plates, and bacterial suspensions are added to achieve a final inoculum of approximately 5×10⁵ CFU/mL. Plates are incubated at 37°C for 18-24 hours, and the MIC is determined as the lowest concentration that inhibits visible bacterial growth.
|
| Animal Protocol |
Intraperitoneal injection of Escherichia coli strain MB5746 (5×104 CFU/mouse) is used to infect DBA/2J mice. The infection is treated with three subcutaneous injections of either ciprofloxacin (0.5 mg/kg) or Ribocil-C (30, 60, 120 mg/kg) over a 24-hour period. Five mice per group have their spleens aseptically removed, and the reduction of log[CFU per g spleen tissue] is computed based on the amount of bacteria present in the spleens of the control group that received a 10% DMSO treatment[2].
The in vivo efficacy of Ribocil-C is evaluated in a mouse model of bacterial infection. Immunocompetent mice are infected with a bacterial pathogen (e.g., S. aureus) via intravenous or intraperitoneal injection. After infection, mice are treated with Ribocil-C at doses of 60 mg/kg and 120 mg/kg, administered orally or intraperitoneally. At the end of the treatment period (e.g., 24-48 hours post-infection), animals are euthanized, and target organs (e.g., spleen, liver, kidneys) are collected. The bacterial load in these organs is determined by homogenizing the tissue and plating serial dilutions on agar plates to count CFU. Efficacy is expressed as the log10 reduction in CFU compared to the untreated control group. |
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for Ribocil-C, such as half-life, bioavailability, or volume of distribution, are not provided in the available sources. The compound is a small molecule with a molecular weight of 419.50. It is soluble in DMSO at 85 mg/mL (202.62 mM). Standard pharmacokinetic studies would typically involve administering the compound to rodents and measuring plasma concentrations over time using LC-MS/MS to determine key PK parameters.
|
| Toxicity/Toxicokinetics |
In a mouse model, Ribocil-C at doses of 60 mg/kg and 120 mg/kg did not cause significant mortality or toxicity. This suggests that the compound has a favorable safety profile at therapeutically relevant doses. As a research compound, it is intended for laboratory use only and is not approved for human therapeutic applications. The compound is stored at low temperature, with powder stable for 3 years at -20°C.
|
| References | |
| Additional Infomation |
Ribocil-C is a highly selective inhibitor of the bacterial riboflavin riboswitch. It is a synthetic analogue of flavin mononucleotide (FMN). The compound demonstrates broad-spectrum activity against various bacterial strains, including drug-resistant pathogens. It is supplied with a purity of 99.69% for research purposes. Ribocil-C is stored as a powder at -20°C for long-term stability.
|
| Molecular Formula |
C21H21N7OS
|
|---|---|
| Molecular Weight |
419.5027
|
| Exact Mass |
419.152
|
| Elemental Analysis |
C, 60.13; H, 5.05; N, 23.37; O, 3.81; S, 7.64
|
| CAS # |
1825355-56-3
|
| Related CAS # |
Ribocil;1381289-58-2;Ribocil-C (R enantiomer);2177266-81-6;Ribocil B;1825355-55-2;Ribocil-C Racemate;2309762-18-1
|
| PubChem CID |
136981150
|
| Appearance |
Solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
672.0±65.0 °C at 760 mmHg
|
| Flash Point |
360.2±34.3 °C
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
| Index of Refraction |
1.771
|
| LogP |
1.25
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
30
|
| Complexity |
693
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
S1C([H])=C([H])C([H])=C1C1=C([H])C(N([H])C(C2([H])C([H])([H])N(C([H])([H])C3=C([H])N(C4N=C([H])C([H])=C([H])N=4)C([H])=N3)C([H])([H])C([H])([H])C2([H])[H])=N1)=O
|
| InChi Key |
UVDVCDUBJWYRJW-HNNXBMFYSA-N
|
| InChi Code |
InChI=1S/C21H21N7OS/c29-19-10-17(18-5-2-9-30-18)25-20(26-19)15-4-1-8-27(11-15)12-16-13-28(14-24-16)21-22-6-3-7-23-21/h2-3,5-7,9-10,13-15H,1,4,8,11-12H2,(H,25,26,29)/t15-/m0/s1
|
| Chemical Name |
2-[(3S)-1-[[1-(2-Pyrimidinyl)-1H-imidazol-4-yl]methyl]-3-piperidinyl]-6-(2-thienyl)-4(3H)-pyrimidinone
|
| Synonyms |
Ribocil-C
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~110 mg/mL (~262.22 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.75 mg/mL (6.56 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.75 mg/mL (6.56 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: 10% DMSO+90% Corn Oil: ≥ 2.75 mg/mL (6.56 mM) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3838 mL | 11.9190 mL | 23.8379 mL | |
| 5 mM | 0.4768 mL | 2.3838 mL | 4.7676 mL | |
| 10 mM | 0.2384 mL | 1.1919 mL | 2.3838 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA